Consistently, analysis of TCGA and the REMBRANDT cohorts demonstrated that patients with glioma exhibiting lower CASP6 expression levels had longer survival (P < 0.0001) (Supplementary Figures 2A, 3A). Here, CASP6 is linked to central nervous system cancer.